Skip to main content

Clinical Trials to Treat Kidney (Renal Cell) Cancer

Trials 1-25 of 127

Comparing the Outcome of Immunotherapy-Based Drug Combination Therapy with or without Surgery to Remove the Kidney in Metastatic Kidney Cancer, the PROBE Trial
Status: Active
Location: 454 locations
Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) after Surgery to Remove all Known Sites of Kidney Cancer
Status: Active
Location: 418 locations
Testing the Addition of Stereotactic Radiation Therapy with Immune Therapy for the Treatment of Patients with Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial
Status: Active
Location: 286 locations
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) with One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
Status: Active
Location: 481 locations
Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney Cancer
Status: Active
Location: 107 locations
Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma
Status: Active
Location: 36 locations
Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers
Status: Active
Location: 23 locations
Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma
Status: Active
Location: 17 locations
KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors
Status: Active
Location: 18 locations
Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors
Status: Active
Location: 16 locations
A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors
Status: Active
Location: 14 locations
Stereotactic Body Radiation Therapy for the Treatment of Metastatic Renal Cell Carcinoma in Patients with Oligoprogression on Immune Checkpoint Inhibitors
Status: Active
Location: 12 locations
A Study of HC-7366 in Combination With Belzutifan (WELIREG™) in Patients With Renal Cell Carcinoma
Status: Active
Location: 12 locations
A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors
Status: Active
Location: 15 locations
A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression
Status: Active
Location: 11 locations
Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors
Status: Active
Location: 10 locations
Abemaciclib and Cabozantinib for the Treatment of Stage IV Clear Cell or Translocation-Associated Renal Cell Carcinoma in Patients Refractory to Immune Checkpoint Blockade Treatment
Status: Active
Location: 8 locations
Cemiplimab and Fianlimab before Surgery for the Treatment of Patients with Locally Advanced Kidney Cancer Undergoing Nephrectomy
Status: Active
Location: 7 locations
Tivozanib and Nivolumab for the Treatment of Patients with Metastatic Non-clear Cell Renal Cell Carcinoma, The FORTUNE Trial
Status: Active
Location: 7 locations
A First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works in Adult Participants Who Have Cancer With Tumors That Have Spread in Their Body
Status: Active
Location: 8 locations
A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid Tumors
Status: Active
Location: 7 locations
Lattice Radiation Therapy to Treat Solid Tumor Cancer That Has Spread to Soft Tissue
Status: Active
Location: 7 locations
Nivolumab, Relatlimab and Ipilimumab versus Nivolumab and Ipilimumab for the Treatment of Untreated Stage IV Renal Cell Cancer
Status: Active
Location: 6 locations
Genetic Testing to Select Therapy for the Treatment of Advanced or Metastatic Kidney Cancer, OPTIC RCC Study
Status: Active
Location: 5 locations
Alternate Cabozantinib Dosing Schedule Alone and in Combination with Nivolumab for the Treatment of Metastatic Kidney Cancer and Neuroendocrine Tumors
Status: Active
Location: 5 locations